BTAI-logo-png-220x123.png
BioXcel Therapeutics to Present at ThinkEquity Conference
October 29, 2024 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in...
BTAI-logo-png-220x123.png
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
October 15, 2024 07:00 ET | BioXcel Therapeutics
Phase 2a efficacy and safety trial enrollment initiation expected in H1 2025 ~40 million Americans go to emergency department annually after a traumatic experience 1 Second externally funded...
BTAI-logo-png-220x123.png
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
September 19, 2024 07:00 ET | BioXcel Therapeutics
Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia Submitted protocol to FDA for TRANQUILITY In-Care pivotal Phase 3 trial...
BTAI-logo-png-220x123.png
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
September 05, 2024 07:00 ET | BioXcel Therapeutics
Estimated 23 million annual agitation episodes in the at-home setting 1-3  No FDA-approved therapies in the at-home setting for acute treatment of agitation associated with bipolar disorders or...
BTAI-logo-png-220x123.png
BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
August 07, 2024 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Aug. 07, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in...
BTAI-logo-png-220x123.png
BioXcel Therapeutics Reports Second Quarter 2024 Financial Results
August 06, 2024 07:00 ET | BioXcel Therapeutics
Planning initiation of SERENITY At-Home pivotal Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia Advancing plans...
BTAI-logo-png-220x123.png
BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024
July 30, 2024 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., July 30, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in...
BTAI-logo-png-220x123.png
BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
July 16, 2024 07:00 ET | BioXcel Therapeutics
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter...
PMR Study Graph_4_24_25
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
June 25, 2024 07:00 ET | BioXcel Therapeutics
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction...
BTAI-logo-png-220x123.png
BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference
May 28, 2024 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in...